DICE Therapeutics IncDICE has announced positive topline data from its Phase 1 trial of DC-806, an oral small molecule antagonist of the pro-inflammatory cytokine IL-17.
Following four weeks of treatment, the mean percentage reduction in Psoriasis Area and Severity Index (PASI) from baseline was 43.7% in the high-dose group compared to 13.3% in the placebo group. Reduction in PASI was an exploratory endpoint with no correction for multiplicity.
Exploratory biomarker data demonstrated dose-dependent IL-17 target engagement, rapid onset of action, and pharmacodynamic effects consistent with direct inhibition of IL-17 signaling.
Data across all three cohorts showed DC-806 was well tolerated, with a favorable safety profile at all dose levels evaluated with no serious adverse events.
DC-806 demonstrated a robust PK profile and clear pharmacodynamic effects on two distinct biomarkers at both high and low doses of DC-806.
DICE plans to advance DC-806 into a dose-ranging Phase 2b trial in patients with moderate-to-severe psoriasis.
The company plans to submit an investigational new drug (IND) application with the FDA in the first half of 2023 and initiate Phase 2b development.
Price Action: DICE stock is 99.2% at $49.10 during the premarket session on the last check Tuesday.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
